{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:55:23Z","timestamp":1787028923450,"version":"build-2736575974"},"reference-count":141,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Small intestinal bacterial overgrowth (SIBO) refers to an abnormal increase in the number of bacteria in the small intestine and is observed in various diseases. SIBO can also develop after long-term use of proton pump inhibitors (drug-induced SIBO), bariatric surgery, gastrectomy, and other surgeries (postoperative SIBO). The aim of this narrative review is to summarize all of the published information on the treatment of SIBO in as much detail as possible and present it separately for each specific disease and intervention associated with SIBO. The most extensively studied drug for the treatment of SIBO is rifaximin. It eliminates SIBO in 63% of cases; however, most studies lack a control group. Small RCTs assessing the effects of this antibiotic on SIBO have reported conflicting results, and a meta-analysis showed no effect. A large RCT is required to verify the results of uncontrolled studies. Neomycin and norfloxacin showed efficacy in the treatment of SIBO in single RCTs, with elimination rates of 20 and 100%, respectively. Ciprofloxacin, rifamycin, metronidazole, and other antibiotics, as well as ursodeoxycholic acid, showed positive effects for the treatment of SIBO, but only in uncontrolled studies or in comparison with rifaximin or other drugs. The reported elimination rates were 54%, 67%, 79%, and 75%, respectively. Eradication therapy for Helicobacter pylori infection eliminated SIBO at a rate of approximately 70%. Probiotics have been tested for treatment of SIBO in various diseases. VSL#3 and Saccharomyces boulardii CNCM I-745 were effective in RCTs, with elimination rates of 58% and 80%, respectively. In conclusion, when selecting SIBO treatment regimens, those that have demonstrated the greatest efficacy for a specific concomitant disease should be preferred, despite the generally low level of evidence supporting these approaches in most cases.<\/jats:p>","DOI":"10.3390\/medsci14020300","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:48:35Z","timestamp":1781138915000},"page":"300","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Gastrointestinal, Hepatic, Endocrine, Neurological, and Postoperative Diseases: A Comprehensive Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-1636","authenticated-orcid":false,"given":"Roman","family":"Maslennikov","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia"},{"name":"Scientific and Technological Institute of Metabolic Health, Sechenov University, Moscow 119435, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6315-5520","authenticated-orcid":false,"given":"Victoria","family":"Agarkova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia"},{"name":"Scientific and Technological Institute of Metabolic Health, Sechenov University, Moscow 119435, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Poluektova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia"},{"name":"Scientific and Technological Institute of Metabolic Health, Sechenov University, Moscow 119435, Russia"},{"name":"Scientific Community for Human Microbiome Research, Moscow 119435, Russia"},{"name":"Reference Center \u201cHuman Microbiota\u201d, Moscow 119435, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoly","family":"Ulyanin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia"},{"name":"Scientific and Technological Institute of Metabolic Health, Sechenov University, Moscow 119435, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Zolnikova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia"},{"name":"Scientific and Technological Institute of Metabolic Health, Sechenov University, Moscow 119435, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6154-8163","authenticated-orcid":false,"given":"Anastasia","family":"Kurbatova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6244-1088","authenticated-orcid":false,"given":"Evgenii","family":"Kozlov","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Allergy, Sechenov University, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Demina","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-3807","authenticated-orcid":false,"given":"Yury","family":"Zharikov","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy and Histology, Sechenov University, Moscow 125009, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Sigidaev","sequence":"additional","affiliation":[{"name":"Department of Clinical Disciplines, Tyumen State Medical University, Tyumen 625023, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Ivashkin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia"},{"name":"Scientific and Technological Institute of Metabolic Health, Sechenov University, Moscow 119435, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1053\/j.gastro.2022.04.002","article-title":"Small Intestinal Bacterial Overgrowth-Pathophysiology and Its Implications for Definition and Management","volume":"163","author":"Bushyhead","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12664-022-01292-x","article-title":"Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: An initiative of the Indian Neurogastroenterology and Motility Association","volume":"41","author":"Ghoshal","year":"2022","journal-title":"Indian J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.22416\/1382-4376-2022-32-3-68-85","article-title":"Practical Recommendation of the Scientific Community for Human Microbiome Research (CHMR) and the Russian Gastroenterological Association (RGA) on Small Intestinal Bacterial Overgrowth in Adults","volume":"32","author":"Ivashkin","year":"2022","journal-title":"Russ. J. Gastroenterol. Hepatol. Coloproctol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.22416\/1382-4376-2024-34-4-64-74","article-title":"Metabolic Profiles of the Gut Microbiota in Patients with Different Stages of Metabolism Dysfunction-Associated Fatty Liver Disease","volume":"34","author":"Cao","year":"2024","journal-title":"Russ. J. Gastroenterol. Hepatol. Coloproct."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MPG.0000000000003245","article-title":"An ESPGHAN Position Paper on the Use of Breath Testing in Paediatric Gastroenterology","volume":"74","author":"Broekaert","year":"2022","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.14309\/ajg.0000000000001110","article-title":"How the North American Consensus Protocol Affects the Performance of Glucose Breath Testing for Bacterial Overgrowth Versus a Traditional Method","volume":"116","author":"Baker","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5056\/jnm19113","article-title":"Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis","volume":"26","author":"Losurdo","year":"2020","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.cgh.2021.09.035","article-title":"Distinctive Clinical Correlates of Small Intestinal Bacterial Overgrowth with Methanogens","volume":"20","author":"Madigan","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"024001","DOI":"10.1088\/1752-7155\/7\/2\/024001","article-title":"The importance of methane breath testing: A review","volume":"7","author":"Ledochowski","year":"2013","journal-title":"J. Breath Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gudan, A., Jamio\u0142-Milc, D., Hawry\u0142kowicz, V., Skonieczna-\u017bydecka, K., and Stachowska, E. (2022). The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis\u2014A Systematic Review, Meta-Analysis and Meta-Regression. Nutrients, 14.","DOI":"10.3390\/nu14245261"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12072-018-9898-2","article-title":"Small intestinal bacterial overgrowth in cirrhosis: Systematic review and metaanalysis","volume":"12","author":"Maslennikov","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Efremova, I., Maslennikov, R., Alieva, A., Poluektova, E., and Ivashkin, V. (2023). Small Intestinal Bacterial Overgrowth Is Associated with Poor Prognosis in Cirrhosis. Microorganisms, 11.","DOI":"10.3390\/microorganisms11041017"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Efremova, I., Maslennikov, R., Zharkova, M., Poluektova, E., Benuni, N., Kotusov, A., Demina, T., Ivleva, A., Adzhieva, F., and Krylova, T. (2024). Efficacy and Safety of a Probiotic Containing Saccharomyces boulardii CNCM I-745 in the Treatment of Small Intestinal Bacterial Overgrowth in Decompensated Cirrhosis: Randomized, Placebo-Controlled Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13030919"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.14740\/jocmr4320","article-title":"Predictors of Small Intestinal Bacterial Overgrowth in Symptomatic Patients Referred for Breath Testing","volume":"12","author":"Kiow","year":"2020","journal-title":"J. Clin. Med. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00556","DOI":"10.14309\/ctg.0000000000000556","article-title":"Small Intestinal Bacterial Overgrowths and Intestinal Methanogen Overgrowths Breath Testing in a Real-Life French Cohort","volume":"14","author":"Plauzolles","year":"2023","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/jgh.14938","article-title":"A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome","volume":"35","author":"Ghoshal","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.14309\/ajg.0000000000000504","article-title":"Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies","volume":"115","author":"Shah","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00535-017-1371-9","article-title":"Meta-analysis: Proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth","volume":"53","author":"Su","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1007\/s11695-022-06299-z","article-title":"Small Intestinal Bacterial Overgrowth in Patients with Roux-en-Y Gastric Bypass and OneAnastomosis Gastric Bypass","volume":"32","author":"Novljan","year":"2022","journal-title":"Obes. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kaniel, O., Sherf-Dagan, S., Szold, A., Langer, P., Khalfin, B., Kessler, Y., Raziel, A., Sakran, N., Motro, Y., and Goitein, D. (2022). The Effects of One Anastomosis Gastric Bypass Surgery on the Gastrointestinal Tract. Nutrients, 14.","DOI":"10.3390\/nu14020304"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.3748\/wjg.v29.i22.3400","article-title":"Epidemiology of small intestinal bacterial overgrowth","volume":"29","author":"Efremova","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4103\/2230-8210.131155","article-title":"Link between hypothyroidism and small intestinal bacterial overgrowth","volume":"18","author":"Patil","year":"2014","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1007\/s10067-020-05549-8","article-title":"Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: A systematic review and meta-analysis","volume":"40","author":"Feng","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_24","first-page":"334","article-title":"Bacterial overgrowth and lactose intolerance: How to best assess","volume":"25","author":"Ghafoor","year":"2022","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.14309\/ajg.0000000000000200","article-title":"Small Intestinal Bacterial Overgrowth Is Common in Chronic Pancreatitis and Associates With Diabetes, Chronic Pancreatitis Severity, Low Zinc Levels, and Opiate Use","volume":"114","author":"Lee","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/00365521.2012.668932","article-title":"Erosive esophagitis may be related to small intestinal bacterial overgrowth","volume":"47","author":"Kim","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/1751-2980.13189","article-title":"Impact of small intestinal bacterial overgrowth on symptoms and quality of life in irritable bowel syndrome","volume":"24","author":"Chuah","year":"2023","journal-title":"J. Dig. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e24107","DOI":"10.1590\/s0004-2803.24612024-107","article-title":"Diagnosis and treatment of small intestinal bacterial overgrowth: An official position paper from the brazilian federation of gastroenterology","volume":"62","author":"Silva","year":"2025","journal-title":"Arq. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2020.06.090","article-title":"AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review","volume":"159","author":"Quigley","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Martyniak, A., W\u00f3jcicka, M., Rogatko, I., Piskorz, T., and Tomasik, P.J. (2025). A Comprehensive Review of the Usefulness of Prebiotics, Probiotics, and Postbiotics in the Diagnosis and Treatment of Small Intestine Bacterial Overgrowth. Microorganisms, 13.","DOI":"10.3390\/microorganisms13010057"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00078","DOI":"10.14309\/ctg.0000000000000078","article-title":"Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management","volume":"10","author":"Rao","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1080\/17474124.2021.2005579","article-title":"Efficacy of rifaximin in treating with small intestine bacterial overgrowth: A systematic review and meta-analysis","volume":"15","author":"Wang","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12664-018-0901-6","article-title":"A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study","volume":"37","author":"Ghoshal","year":"2018","journal-title":"Indian J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"117283","DOI":"10.1016\/j.biopha.2024.117283","article-title":"Therapeutic potential of rifaximin in liver diseases","volume":"178","author":"Yang","year":"2024","journal-title":"BioMed. Pharmacother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e2400356","DOI":"10.1002\/ardp.202400356","article-title":"Rifaximin and alternative agents in the management of irritable bowel syndrome: A comprehensive review","volume":"357","author":"Comoglu","year":"2024","journal-title":"Arch. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.15403\/jgld-4871","article-title":"Update on the Role of Rifaximin in Digestive Diseases","volume":"32","author":"Dumitrascu","year":"2023","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yu, X., Jin, Y., Zhou, W., Xiao, T., Wu, Z., Su, J., Gao, H., Shen, P., Zheng, B., and Luo, Q. (2022). Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.761192"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5056\/jnm20080","article-title":"Fecal Microbiota Alterations and Small Intestinal Bacterial Overgrowth in Functional Abdominal Bloating\/Distention","volume":"26","author":"Noh","year":"2020","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_39","first-page":"1245","article-title":"Small intestinal bacterial overgrowth in patients with functional gastrointestinal diseases","volume":"135","author":"Madrid","year":"2007","journal-title":"Rev. Med. Chil."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zhuang, X., Tian, Z., Luo, M., and Xiong, L. (2020). Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-01336-6"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhuang, X., Tian, Z., Li, L., Zeng, Z., Chen, M., and Xiong, L. (2018). Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.01600"},{"key":"ref_42","first-page":"139","article-title":"Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: Clinical profiles and effects of antibiotic trial","volume":"52","author":"Majewski","year":"2007","journal-title":"Adv. Med. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"104936","DOI":"10.1016\/j.phrs.2020.104936","article-title":"Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome","volume":"159","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.14309\/ajg.0000000000000444","article-title":"Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea","volume":"114","author":"Rezaie","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.3748\/wjg.15.2628","article-title":"Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with Rifaximin","volume":"15","author":"Peralta","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/apt.12087","article-title":"Rifaximin treatment of the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months","volume":"36","author":"Meyrat","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5056\/jnm22187","article-title":"Symptomatic Response to Antibiotics in Patients With Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-analysis","volume":"30","author":"Takakura","year":"2024","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/030006058801600410","article-title":"Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin","volume":"16","author":"Corazza","year":"1988","journal-title":"J. Int. Med. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2036.2005.02516.x","article-title":"Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth","volume":"22","author":"Lauritano","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1365-2036.2007.03259.x","article-title":"High dosage rifaximin for the treatment of small intestinal bacterial overgrowth","volume":"25","author":"Scarpellini","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_51","first-page":"143","article-title":"Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania","volume":"52","author":"Moraru","year":"2014","journal-title":"Rom. J. Intern. Med."},{"key":"ref_52","first-page":"143","article-title":"Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study","volume":"51","author":"Moraru","year":"2013","journal-title":"Rom. J. Intern. Med."},{"key":"ref_53","first-page":"89","article-title":"Small intestine bacterial overgrowth in irritable bowel syndrome: A retrospective study with rifaximin","volume":"52","author":"Cuoco","year":"2006","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1756283X15621231","article-title":"Refining small intestinal bacterial overgrowth diagnosis by means of carbohydrate specificity: A proof-of-concept study","volume":"9","author":"Enko","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MAJ.0b013e3180536784","article-title":"Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth","volume":"333","author":"Majewski","year":"2007","journal-title":"Am. J. Med. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.3748\/wjg.v13.i45.6016","article-title":"Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: An observation on non-absorbable antibiotics","volume":"13","author":"Esposito","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_57","first-page":"1314","article-title":"Rifaximin treatment of small intestinal bacterial overgrowth in children with irritable bowel syndrome","volume":"17","author":"Scarpellini","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1365-2036.2010.04436.x","article-title":"Clinical trial: The combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth","volume":"32","author":"Furnari","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5056\/jnm23029","article-title":"Effect of Trimebutine and Rifaximin on Breath Hydrogen and Methane by Glucose Breath Test in Patients With Functional Bloating: A Randomized Double-blind Clinical Trial","volume":"30","author":"Jo","year":"2024","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12941-014-0049-x","article-title":"Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome","volume":"13","author":"Boltin","year":"2014","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/j.1572-0241.2008.02030.x","article-title":"Small intestinal bacterial overgrowth recurrence after antibiotic therapy","volume":"103","author":"Lauritano","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/ueg2.12116","article-title":"The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth","volume":"9","author":"Richard","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Connor, B.A., Rogova, M., Garcia, J., Gardner, M., Waraich, C., and Averill, V. (2025). A randomized open label pilot study evaluating the efficacy of two dosing regimens of rifamycin SV MMX in the treatment of small intestinal bacterial overgrowth. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-03804-3"},{"key":"ref_64","first-page":"82","article-title":"Association of food patterns with different forms of small intestinal bacterial overgroth syndrome and treatment efficacy","volume":"91","author":"Pilipenko","year":"2019","journal-title":"Ter. Arkh"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/MPG.0b013e3182952e93","article-title":"Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum","volume":"57","author":"Tahan","year":"2013","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.dld.2020.10.032","article-title":"COLIGENTA treatment of small intestinal bacterial overgrowth. Results of an open study","volume":"53","author":"Bouchoucha","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2036.2000.00751.x","article-title":"Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth","volume":"14","author":"Malservisi","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_68","first-page":"111","article-title":"Antibiotic therapy in small intestinal bacterial overgrowth: Rifaximin versus metronidazole","volume":"13","author":"Lauritano","year":"2009","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_69","first-page":"54","article-title":"Treatment of small intestinal bacterial overgrowth in Chilean patients with irritable bowel syndrome: A prospective and comparative study","volume":"90","author":"Landskron","year":"2025","journal-title":"Rev. Gastroenterol. Mex."},{"key":"ref_70","first-page":"412","article-title":"Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study","volume":"98","author":"Pimentel","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MEG.0000000000000557","article-title":"A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: A randomized, double-blind, placebo-controlled trial","volume":"28","author":"Ghoshal","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_72","first-page":"604","article-title":"Evaluating the efficacy of probiotic on treatment in patients with small intestinal bacterial overgrowth (SIBO)\u2014A pilot study","volume":"140","author":"Khalighi","year":"2014","journal-title":"Indian J. Med. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0016-5085(99)70336-7","article-title":"Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: A crossover, randomized trial","volume":"117","author":"Attar","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s10620-018-5344-5","article-title":"Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome","volume":"64","author":"Tuteja","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MPG.0b013e3181effa3b","article-title":"Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain","volume":"52","author":"Collins","year":"2011","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s12602-019-09628-4","article-title":"The Evolution of Human Probiotics: Challenges and Prospects","volume":"12","author":"Trush","year":"2020","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.22416\/1382-4376-2024-117-312","article-title":"Methodological Guidelines of the Scientific Community for Human Microbiome Research (CHMR) and the Russian Gastroenterology Association (RGA) on the Use of Probiotics, Prebiotics, Synbiotics, Metabiotics and Functional Foods Enriched with Them for the Treatment and Prevention of Gastrointestinal Diseases in Adults and Children","volume":"34","author":"Ivashkin","year":"2024","journal-title":"Russ. J. Gastroenterol. Hepatol. Coloproctology"},{"key":"ref_78","first-page":"10","article-title":"Comparative assessment of Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus and Saccharomyces boulardii efficacy at diarrheal variant of irritable bowel syndrome","volume":"25","author":"Ivashkin","year":"2015","journal-title":"Russ. J. Gastroenterol. Hepatol. Coloproctology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8791916","DOI":"10.1155\/2018\/8791916","article-title":"The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study","volume":"2018","author":"Lee","year":"2018","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4181748","DOI":"10.1155\/2020\/4181748","article-title":"Effect of Combined Live Probiotics Alleviating the Gastrointestinal Symptoms of Functional Bowel Disorders","volume":"2020","author":"Shi","year":"2020","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3920\/BM2018.0008","article-title":"Bifidobacterium infantis M-63 improves mental health in victims with irritable bowel syndrome developed after a major flood disaster","volume":"10","author":"Ma","year":"2019","journal-title":"Benef. Microbes"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7453\/gahmj.2014.019","article-title":"Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth","volume":"3","author":"Chedid","year":"2014","journal-title":"Glob. Adv. Health Med."},{"key":"ref_83","first-page":"21","article-title":"Comparative efficacy of Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus composition and prucalopride in treatment of constipation variant of irritable bowel syndrome","volume":"25","author":"Ivashkin","year":"2015","journal-title":"Russ. J. Gastroenterol. Hepatol. Coloproctology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2147\/TCRM.S269330","article-title":"Current Opinion on Prucalopride in Gastroparesis and Chronic Constipation Treatment: A Focus on Patient Selection and Safety","volume":"17","author":"Hong","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.cgh.2025.03.002","article-title":"Effect, tolerability, and safety of exclusive palatable elemental diet in patients with intestinal microbial overgrowth","volume":"23","author":"Rezaie","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.amjms.2016.05.012","article-title":"Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation","volume":"352","author":"Sarosiek","year":"2016","journal-title":"Am. J. Med. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10620-023-08155-1","article-title":"Efficacy and Safety of Pea Protein and Xyloglucan Versus Simethicone in Functional Abdominal Bloating and Distension","volume":"69","author":"Petrisor","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Lopresti, A.L., Smith, S.J., Rea, A., and Michel, S. (2021). Efficacy of a curcumin extract (Curcugen\u2122) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: A randomised, double-blind, placebo-controlled study. BMC Complement. Med. Ther., 21.","DOI":"10.1186\/s12906-021-03220-6"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1007\/s10620-013-2694-x","article-title":"Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease","volume":"58","author":"Rana","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/apt.15133","article-title":"Systematic review with meta-analysis: The prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease","volume":"49","author":"Hah","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10620-006-3155-6","article-title":"Transient lactose malabsorption in patients affected by symptomatic uncomplicated diverticular disease of the colon","volume":"51","author":"Tursi","year":"2006","journal-title":"Dig. Dis. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5056\/jnm22023","article-title":"Lactase Deficiency Diagnosed by Endoscopic Biopsy-based Method is Associated With Positivity to Glucose Breath Test","volume":"29","author":"Jo","year":"2023","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/jpen.1667","article-title":"Risk Factors of Ambulatory Central Line-Associated Bloodstream Infection in Pediatric Short Bowel Syndrome","volume":"44","author":"Seddik","year":"2020","journal-title":"JPEN J. Parenter. Enter. Nutr."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1111\/jgh.15920","article-title":"Links between celiac disease and small intestinal bacterial overgrowth: A systematic review and meta-analysis","volume":"37","author":"Shah","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1185\/0300799009117003","article-title":"Effect of rifaximin on intestinal bacterial overgrowth in Crohn\u2019s disease as assessed by the H2-Glucose Breath Test","volume":"16","author":"Biancone","year":"2000","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1046\/j.1365-2036.2003.01800.x","article-title":"Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn\u2019s disease","volume":"18","author":"Castiglione","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2036.2007.03266.x","article-title":"Interaction between rifaximin and dietary fibre in patients with diverticular disease","volume":"25","author":"Pomerri","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.3748\/wjg.v11.i18.2773","article-title":"Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon","volume":"11","author":"Tursi","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s10620-024-08767-1","article-title":"Rifaximin-Alpha Increases Lactase Activity in Patients with Irritable Bowel Syndrome Without Constipation and Small Intestinal Bacterial Overgrowth","volume":"70","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Velimirovic, M., Osterman, V., Prislan, A., and Pintar, T. (2025). Small Intestinal Bacterial Overgrowth in Children with Short Bowel Syndrome: Risk Factors, Clinical Presentation and Management\u2014A Single-Center Experience. Children, 12.","DOI":"10.3390\/children12030351"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1572-0241.2003.07379.x","article-title":"High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal","volume":"98","author":"Tursi","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s10620-011-1719-6","article-title":"Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease","volume":"56","author":"Chang","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"135","DOI":"10.12938\/bmfh.2023-080","article-title":"Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: A randomized, double-blind, placebo-controlled, phase II\u2014A exploratory trial","volume":"43","author":"Ohkubo","year":"2024","journal-title":"Biosci. Microbiota Food Health"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"9320","DOI":"10.12998\/wjcc.v9.i31.9320","article-title":"Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link?","volume":"9","author":"Maslennikov","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"964","DOI":"10.5152\/tjg.2019.18551","article-title":"Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis?","volume":"30","author":"Maslennikov","year":"2019","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_106","first-page":"2954","article-title":"Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis","volume":"8","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Yokoyama, K., Sakamaki, A., Takahashi, K., Naruse, T., Sato, C., Kawata, Y., Tominaga, K., Abe, H., Sato, H., and Tsuchiya, A. (2022). Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264459"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1038\/s41598-020-67171-7","article-title":"Minimal Hepatic Encephalopathy: Effect of H. pylori infection and small intestinal bacterial overgrowth treatment on clinical outcomes","volume":"10","author":"Abid","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cgh.2013.11.006","article-title":"Probiotics prevent hepatic encephalopathy in patients with cirrhosis: A randomized controlled trial","volume":"12","author":"Lunia","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"016005","DOI":"10.1088\/1752-7163\/ad8e7e","article-title":"Therapeutic efficacy of a probiotic preparation on idiopathic halitosis: A retrospective observational study","volume":"19","author":"Li","year":"2024","journal-title":"J. Breath. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e00072","DOI":"10.14309\/ctg.0000000000000072","article-title":"Factors That Affect Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Pancreatitis: A Systematic Review, Meta-Analysis, and Meta-Regression","volume":"10","author":"Babar","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1185\/03007999909115173","article-title":"Intestinal bacterial overgrowth during chronic pancreatitis","volume":"15","author":"Trespi","year":"1999","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10620-024-08279-y","article-title":"Influence of Helicobacter pylori Infection and Eradication on Small Intestinal Bacterial Overgrowth and Abdominal Symptoms","volume":"69","author":"Wang","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_114","first-page":"213","article-title":"Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection","volume":"13","author":"Konrad","year":"2018","journal-title":"Prz. Gastroenterol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kim, B.T., Kim, K.M., and Kim, K.N. (2020). The Effect of Ursodeoxycholic Acid on Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia: A Pilot Randomized Controlled Trial. Nutrients, 12.","DOI":"10.3390\/nu12051410"},{"key":"ref_116","first-page":"523","article-title":"Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: Prevalence and role of rifaximin in its management in primary care","volume":"69","author":"Lopetuso","year":"2023","journal-title":"Minerva Gastroenterol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s11695-024-07117-4","article-title":"Effects of Probiotic Use on Gastrointestinal Symptoms in the Late Postoperative Period of Bariatric Surgery: A Cross-Over, Randomized, Triple-Blind, Placebo-Controlled Study","volume":"34","author":"Wagner","year":"2024","journal-title":"Obes. Surg."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11695-020-04900-x","article-title":"Effects of Probiotics Supplementation on Gastrointestinal Symptoms and SIBO after Roux-en-Y Gastric Bypass: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"31","author":"Wagner","year":"2021","journal-title":"Obes. Surg."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s11695-020-04477-5","article-title":"Study of Small Intestinal Bacterial Overgrowth in a Cohort of Patients with Abdominal Symptoms Who Underwent Bariatric Surgery","volume":"30","author":"Mouillot","year":"2020","journal-title":"Obes. Surg."},{"key":"ref_120","first-page":"1","article-title":"Small intestinal bacterial overgrowth is common after gastrectomy but with little impact on nutritional status","volume":"42","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3892\/mco.2016.807","article-title":"Prevalence and treatment of small intestinal bacterial overgrowth in postoperative patients with colorectal cancer","volume":"4","author":"Deng","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5056\/jnm22168","article-title":"Small Intestinal Bacterial Overgrowth Complicating Gastrointestinal Manifestations of Systemic Sclerosis: A Systematic Review and Meta-analysis","volume":"29","author":"Shah","year":"2023","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s10620-019-05830-0","article-title":"Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis","volume":"65","author":"Jara","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jcf.2011.06.008","article-title":"Oral antibiotic therapy improves fat absorption in cystic fibrosis patients with small intestine bacterial overgrowth","volume":"10","author":"Lisowska","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00535-018-1509-4","article-title":"The role of small intestinal bacterial overgrowth in cystic fibrosis: A randomized case-controlled clinical trial with rifaximin","volume":"54","author":"Furnari","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MPG.0000000000003459","article-title":"PROSPECT GIFT Sub-study Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Changes in Glucose Breath Test in Cystic Fibrosis Patients Treated With 1 Month of Lumacaftor\/Ivacaftor","volume":"75","author":"Gabel","year":"2022","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1210\/jc.2007-0606","article-title":"Association between hypothyroidism and small intestinal bacterial overgrowth","volume":"92","author":"Lauritano","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/fsn3.3948","article-title":"Evaluation of probiotics in the treatment of hypothyroidism in early pregnancy combined with small intestinal bacterial overgrowth","volume":"12","author":"Zhang","year":"2024","journal-title":"Food Sci. Nutr."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1210\/jc.2006-2509","article-title":"Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients","volume":"92","author":"Resmini","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/j.1572-0241.2007.01758.x","article-title":"Small intestinal bacterial overgrowth in patients suffering from scleroderma: Clinical effectiveness of its eradication","volume":"103","author":"Parodi","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"101","DOI":"10.5114\/ada.2020.101468","article-title":"Gut microbiome in systemic sclerosis: A potential therapeutic target","volume":"39","author":"Gerkowicz","year":"2022","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Polkowska-Pruszy\u0144ska, B., Gerkowicz, A., Rawicz-Pruszy\u0144ski, K., and Krasowska, D. (2020). The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO). Diagnostics, 10.","DOI":"10.3390\/diagnostics10080587"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/mds.25522","article-title":"The role of small intestinal bacterial overgrowth in Parkinson\u2019s disease","volume":"28","author":"Fasano","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s13365-019-00756-9","article-title":"The effect of pyridostigmine on small intestinal bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic neuropathies","volume":"25","author":"Nmashie","year":"2019","journal-title":"J. Neurovirol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/2050640614559262","article-title":"Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea","volume":"3","author":"Gravina","year":"2015","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cgh.2008.02.054","article-title":"Small intestinal bacterial overgrowth in rosacea: Clinical effectiveness of its eradication","volume":"6","author":"Parodi","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/apt.70420","article-title":"Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome","volume":"63","author":"Chuah","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"046007","DOI":"10.1088\/1752-7163\/ae0aec","article-title":"Therapeutic effect of the low FODMAPs diet for refractory halitosis associated with small intestinal bacterial overgrowth","volume":"19","author":"Gong","year":"2025","journal-title":"J. Breath Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12934-021-01589-0","article-title":"Evaluation of fecal microbiota transplantation in Parkinson\u2019s disease patients with constipation","volume":"20","author":"Kuai","year":"2021","journal-title":"Microb. Cell Fact."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Xu, F., Li, N., Wang, C., Xing, H., Chen, D., and Wei, Y. (2021). Clinical efficacy of fecal microbiota transplantation for patients with small intestinal bacterial overgrowth: A randomized, placebo-controlled clinic study. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01630-x"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5056\/jnm16074","article-title":"Serial Frozen Fecal Microbiota Transplantation in the Treatment of Chronic Intestinal Pseudo-obstruction: A Preliminary Study","volume":"23","author":"Gu","year":"2017","journal-title":"J. Neurogastroenterol. Motil."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/2\/300\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:06:52Z","timestamp":1781140012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/2\/300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":141,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medsci14020300"],"URL":"https:\/\/doi.org\/10.3390\/medsci14020300","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}